Literature DB >> 14596516

A systematic overview of radiation therapy effects in brain tumours.

Gertrud Berg1, Erik Blomquist, Eva Cavallin-Ståhl.   

Abstract

A systematic review of radiation therapy trials in several tumour types was performed by The Swedish Council of Technology Assessment in Health Care (SBU). The procedures for evaluation of the scientific literature are described separately (Acta Oncol 2003; 42: 357-365). This synthesis of the literature on radiation therapy for brain tumours is based on data from 9 randomized trials and 1 meta-analysis. Moreover, data from 2 prospective studies, 3 retrospective studies and 4 other articles were used. In total, 19 scientific articles are included, involving 4,266 patients. The results were compared with those of a similar overview from 1996 including 11,252 patients. The conclusions reached can be summarized as follows: The conclusion from SBU 129/2 that curative treatment is not available for patients with high-grade malignant glioma (grade III and IV) is still valid. The survival benefit from postoperative radiotherapy compared to supportive care only or chemotherapy is about 3-4 months, as demonstrated in earlier randomized studies. Quality of life is now currently estimated and considered to be of major importance when reporting the outcome of treatment for patients with brain tumours. There is no scientific evidence that radiotherapy using hyper- and hypofractionation leads to longer survival for patients with high-grade malignant glioma than conventional radiotherapy. There is large documentation, but only one randomized study. There is some documentation to support the view that patients with grade IV glioma and poor prognosis can be treated with hypofractionation and with an outcome similar to that after conventional fractionation. A shorter treatment time should be convenient for the patient. Documentation of the benefit of a radiotherapy boost with brachytherapy is limited and no conclusion can be drawn. There is no scientific evidence that radiotherapy prolongs life for patients with low-grade glioma. There are some data supporting that radiotherapy can be used to treat symptoms in patients with low-grade glioma. As no controlled studies have been reported, no firm conclusion can be drawn.

Entities:  

Mesh:

Year:  2003        PMID: 14596516     DOI: 10.1080/02841860310014679

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  13 in total

1.  F-18 FDG PET-CT for predicting survival in patients with recurrent glioma: a prospective study.

Authors:  Amburanjan Santra; Rakesh Kumar; Punit Sharma; Chandrashekhar Bal; Pramod Kumar Julka; Arun Malhotra
Journal:  Neuroradiology       Date:  2011-07-08       Impact factor: 2.804

2.  CpG ODN107 potentiates radiosensitivity of human glioma cells via TLR9-mediated NF-κB activation and NO production.

Authors:  Xiaoli Li; Dan Liu; Xin Liu; Weiwei Jiang; Weiying Zhou; Wei Yan; Yanyan Cen; Bin Li; Guanqun Cao; Guofu Ding; Xueli Pang; Jianguo Sun; Jiang Zheng; Hong Zhou
Journal:  Tumour Biol       Date:  2012-06-28

3.  [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence.

Authors:  S Ceyssens; K Van Laere; T de Groot; J Goffin; G Bormans; L Mortelmans
Journal:  AJNR Am J Neuroradiol       Date:  2006-08       Impact factor: 3.825

4.  Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.

Authors:  Michael D Prados; Kathleen R Lamborn; Susan Chang; Eric Burton; Nicholas Butowski; Mary Malec; Ami Kapadia; Jane Rabbitt; Margaretta S Page; Ann Fedoroff; Dong Xie; Sean K Kelley
Journal:  Neuro Oncol       Date:  2006-01       Impact factor: 12.300

5.  Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker.

Authors:  Taiichi Saito; Muhamad Thohar Arifin; Seiji Hama; Yoshinori Kajiwara; Kazuhiko Sugiyama; Fumiyuki Yamasaki; Toshikazu Hidaka; Kazunori Arita; Kaoru Kurisu
Journal:  J Neurooncol       Date:  2006-12-07       Impact factor: 4.130

6.  Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy.

Authors:  Patrick Beauchesne; Valerie Bernier; Charlotte Carnin; Luc Taillandier; Mohamed Djabri; Laurent Martin; Xavier Michel; Jean-Philippe Maire; Toufic Khalil; Christine Kerr; Thierry Gorlia; Roger Stupp; Remy Pedeux
Journal:  Neuro Oncol       Date:  2010-02-11       Impact factor: 12.300

7.  Local delivery of ferrociphenol lipid nanocapsules followed by external radiotherapy as a synergistic treatment against intracranial 9L glioma xenograft.

Authors:  Emilie Allard; Delphine Jarnet; Anne Vessières; Sandrine Vinchon-Petit; Gérard Jaouen; Jean-Pierre Benoit; Catherine Passirani
Journal:  Pharm Res       Date:  2009-11-12       Impact factor: 4.200

8.  Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab.

Authors:  Jidong Hong; Yuping Peng; Yuping Liao; Wuzhong Jiang; Rui Wei; Lei Huo; Zaide Han; Chaojun Duan; Meizuo Zhong
Journal:  Exp Ther Med       Date:  2012-04-19       Impact factor: 2.447

Review 9.  Brain endothelial cells as pharmacological targets in brain tumors.

Authors:  Michel Demeule; Anthony Régina; Borhane Annabi; Yanick Bertrand; Michel W Bojanowski; Richard Béliveau
Journal:  Mol Neurobiol       Date:  2004-10       Impact factor: 5.590

10.  Carmustine implants for the treatment of newly diagnosed high-grade gliomas: a cost-utility analysis.

Authors:  Gabriel Rogers; Ruth Garside; Stuart Mealing; Martin Pitt; Rob Anderson; Matthew Dyer; Ken Stein; Margaret Somerville
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.